FDA Revokes Emergency Use of Malaria Drugs to Treat Coronavirus, Cites ‘Potential Risks’

U.S. regulators on Monday revoked emergency authorization for malaria drugs promoted by President Donald Trump for treating COVID-19 amid growing evidence they don’t work and could cause deadly side effects.

The Food and Drug Administration said the drugs hydroxychloroquine and chloroquine are unlikely to be effective in treating the coronavirus. Citing reports of heart complications, the FDA said the drugs’ unproven benefits “do not outweigh the known and potential risks.”

Read More

Vice President Pence Tours Mayo Clinic, Criticized by Media for Not Wearing Mask

Vice President Mike Pence praised the innovation and leadership of Mayo Clinic during a Tuesday visit to the distinguished institution’s headquarters in Rochester, Minnesota.

Read More

Commentary: Progressive Woke Orthodoxy Obscures the Truth About the Virus

Americans are acquainted with predictable but ultimately failed progressive efforts to suppress free expression by preemptive invective and politically correct finger-pointing.

To believe that U.S. Supreme Court Justice Brett Kavanaugh’s accusers revealed too many contradictions, too many lacunae, too many episodes of timely amnesia, and too many unsubstantiated accusations in their testimonies was chauvinistically to attack/smear/silence all women’s voices – at least until the same sort of memory-repressed accusations focused on handsy Joe Biden.

To express skepticism that current global temperatures are uniformly rising almost entirely due to human carbon emissions, that this state of affairs poses catastrophic dangers that may end civilization as we know it, and that this emergency can only be addressed by the radical restructuring of global economies is to be rendered a denialist, a crank, a fool.

But these parameters of censorship have a logic and predictability, given their race/class/gender/environmental orthodoxy.

Read More

FDA Issues Emergency Authorization Of Anti-Malaria Drugs As Doctors Herald Results For Coronavirus Patients

The United States Food and Drug Administration issued an emergency use authorization for donated anti-malaria drugs hydroxychloroquine sulfate and chloroquine phosphate as doctors say the drugs are showing positive results for coronavirus patients.

The FDA issued the authorization to allow doctors to distribute and prescribe the anti-malaria drugs to hospitalized teen and adult patients who have coronavirus, the Department of Health and Human Services said in a press release. Doctors may distribute and prescribe the drugs “as appropriate, when a clinical trial is not available or feasible.”

The emergency authorization was issued to the Assistant Secretary for Preparedness and Response’s Biomedical Advanced Research and Development Authority, which is working with the National Institute of Health to plan clinical trials of the drugs.

Read More

Mayo Clinic Says It Can Now Perform Up to 4,000 COVID-19 Tests Daily

Mayo Clinic announced last week that it can now test up to 4,000 clinical samples for SARS-CoV-2, the virus that causes COVID-19, on a daily basis.

Mayo officials said they now have the capacity to process COVID-19 test samples at all Mayo Clinic sites and have started processing test samples from their clients across the state, including eight major health systems.

Read More

FDA Authorizes New 45 Minute Coronavirus Test for Release Next Week

A California-based molecular diagnostics company announced Saturday they will ship a point-of-care test next week that they say can detect SARS-CoV-2, the virus causing COVID-19 in 45 minutes.

Officials at the U.S. Food and Drug Administration gave that company, Cepheid, Emergency Use Authorization to do so, company officials said in a press release.

Called the Xpert Xpress SARS-CoV-2, the test is designed to operate on any of Cepheid’s more than 23,000 automated GeneXpert Systems worldwide, with a detection time of less than one hour.

Read More

President Trump Says FDA Has Approved Testing of Anti-Malaria Drug Chloroquine for Treating Coronavirus

President Donald Trump announced during a Thursday press briefing that the anti-malarial drug chloroquine was approved by the Food and Drug Administration as a possible treatment for the coronavirus.

The announcement comes the day after Breitbart News reported that the medical establishment has known about chloroquine’s effectiveness in treating the virus since at least the 2005 SARS coronavirus outbreak.

“Clinical trials are already underway for many new therapies and we’re working on scaling these to allow many more Americans to access different drugs that have shown really good promise,” President Trump said.

Read More

Trump Administration Ends Contract Supplying Fetal Tissue for Research

by Rachel del Guidice   The Trump administration has ended the government’s contract with a bioscience company that provided human fetal tissue from elective abortions for testing purposes. The Food and Drug Administration no longer will obtain the fetal tissue from California-based Advanced Bioscience Resources Inc., the Department of Health…

Read More

FDA: More Blood Pressure Drugs May Have Shortages After Recalls

by Reuters   Additional shortages of blood pressure drugs in the United States are possible following recent recalls related to traces of a probable carcinogen found in some versions a particular class of hypertension medicines, the U.S. Food and Drug Administration said Friday. The drugs, including valsartan, belong to a…

Read More

Senate DFL Introduces Slate of Identity Politics Bills, Seeks to Loosen Prevention of HIV in Blood Donations

The Minnesota State Senate plans to introduce 92 new pieces of legislation Monday, several of which are backed by the DFL, and focus on LGBT or race issues. Senate File (SF) 95, for instance, urges President Donald Trump and Congress to direct the Food and Drug Administration (FDA) to “revise…

Read More

Dr. Carol M. Swain Commentary: Congress’s Role in Creating America’s Healthcare Crisis

by Dr. Carol M. Swain   In 2017, President-elect Donald Trump sent pharmaceutical stocks into a nosedive by speaking an important truth. Drug companies, he said, are “getting away with murder” with their pricing of lifesaving drugs. True to his word, the president, since his election, has pushed for needed reforms  aimed at…

Read More

Dr. Carol M. Swan Commentary: Congress’s Role in Creating America’s Healthcare Crisis

by Dr. Carol M. Swain   In 2017, President-elect Donald Trump sent pharmaceutical stocks into a nosedive by speaking an important truth. Drug companies, he said, are “getting away with murder” with their pricing of lifesaving drugs. True to his word, the president, since his election, has pushed for needed reforms  aimed at…

Read More

Promise Kept: President Trump’s Landmark ‘Right to Try’ Legislation Curbs Government’s Monopoly on Medicine for Terminally Ill Patients

Trump right to try

In a signing ceremony on Wednesday, President Trump fulfilled another campaign promise by signing legislation nicknamed “Right to Try” that will expand seriously ill patients’ access to experimental treatments that could extent or even save their lives. Mr. Trump called the measure a “fundamental freedom” for people with terminal conditions to…

Read More

Trump Is Following Through On His Pledge To Lower Drug Prices, Here’s The Plan

by Steve Birr   The Trump administration released its blueprint for lowering skyrocketing prescription drug prices Friday, a strategy that has already saved patients nearly $9 billion. President Donald Trump, along with Health and Human Services Secretary Alex Azar, outlined their four-pronged approach to making medications more affordable during an afternoon press…

Read More

President Trump Faces Institutional Obstacles to Overcome U.S. Drug Pricing Fiasco

President Trump is scheduled to deliver his first speech Friday to introduce an overarching plan to confront high drug prices. As a candidate, where he railed against the pharmaceutical industry and accused it of “getting away with murder.” The populist rhetoric appears to be giving way to a more nuanced strategy focused…

Read More